Competition Buzz: The Use of EU Competition Precedents in Brazilian Competition Judgments
Christopher Townley, King’s College
Although CADE does not directly base its judgments on foreign law, when interpreting Brazilian law it refers to EU and US antitrust for ideas on how to develop its own rules and to confirm its own judgments, some believe that this is appropriate. There are many who argue that the Brazilian competition rules governing anti-competitive arrangements aim to protect consumer welfare. If Brazilian and EU competition laws have the same goals, then as long as one takes account of the different institutional and socio-economic contexts (as well as the specific provisions of the competition laws themselves), it makes sense for CADE to rely on the outcomes of similar EU competition decisions to confirm its own judgments.
This paper focuses on the rules that apply to anti-competitive agreements (not including merger agreements) on the EU side. The relevant rule in the European legal order is Article 101 TFEU. The Authors do not examine US antitrust, but a similar point is relevant there, to the extent that US goals diverge from Brazilian ones.
Read the Full Article
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan